Hematopoietic SCT (HSCT) can improve severe and drug-resistant autoimmune diseases (ADs) although sometimes it may have a pathogenic role in their development. Here, we report the case of a young girl who developed arthritis 11 years after allogeneic HSCT. To our knowledge, this is the first case in the literature of juvenile arthritis (JA) following HSCT and we suggest that JA should be considered as new entity among ADs following HSCT.
We report the case of a 14-year-old girl, with no familial history of ADs, who came to our attention with swelling and pain in the proximal interphalangeal (IFP) joint of the second and the third finger of the right hand, painful IFP of the third finger of the left hand accompanied by morning stiffness lasting for 2 h and swelling with functional impairment of hands, wrists and knees. Blood analyses showed increased inflammatory indexes (erythrocyte sedimentation rate, 40 mm; reactive C protein, 2.21 mg/mL), a positive result for antinuclear antibody (ANA; 1:640 in Hep2 cells) and a negative result for rheumatoid factor. The musculoskeletal magnetic resonance imaging (MRI) of the hands (Figure 1 ) showed endoarticular fluid in both carpal bones and in the radioulnar joint with signs of synovitis; synovitis alone was also present in the metacarpophalangeal joint of the second, third and the fourth fingers of the left hand, and the second and the third on the right, IFP of the third finger of the left hand, and second and third of the right hand and the carpometacarpal joint of the first finger bilaterally. Clinical and laboratory findings, together with musculoskeletal MRI allowed us to make the diagnosis of arthritis, resembling juvenile idiopathic arthritis estence oligoarticular ANApositive subtype.
When she was 18-months-old, she was diagnosed of acute lymphoblastic leukaemia type pre-B and started chemotherapy according to the AEIOP LAL 9502 protocol. Owing to a bone marrow relapse, 1 month after the re-induction phase, she started another chemotherapy cycle of second degree (CCG 1941 protocol) and the search for an unrelated donor was initiated, because no HLA-identical family donor was present. When she was 3-years-old, after a conditioning regimen consisting of busulfan, tiothepa and cyclophosphamide, she underwent HSCT from the peripheral-blood stem cell source. The full HLA type was: A 0211, 6811; B 3502, 4001; C 03, 04; DRB1 11041, 15011 for recipient and donor retrospectively, the pair being fully matched for the HLA loci tested. At the time of transplantation, the donor wasn't affected by any AD. Ten months later, during tapering of the immunosuppressive drugs, she presented skin lesions resembling chronic GVHD and started an immunosuppressive regimen with corticosteroid followed by tacrolimus and mycophenolate mofetil. Later she developed functional restrictive respiratory syndrome, ovarian insufficiency (treated with replacement therapy) and a sonographic appearance of thyroiditis without hormonal alterations.
Arthritis was treated with nonsteroidal anti-inflammatory drugs with only a partial relief, promptly replaced with an oral corticosteroid owing to severe polyarticular involvement. After an initial positive clinical response, pain and functional impairment of legs and arms reappeared with morning stiffness and swelling of hands during steroid tapering. For this reason we finally decided to start Methotrexate which was effective and improved the symptomatology. Complete remission was achieved after a few months and now the patient is able to start discontinuing the therapy. Concerning the donor, at the last registered follow up (December 2013) he hadn't developed arthritis or any other ADs and no records of ADs in his family are mentioned.
Autoimmune phenomena are known in both autologous and allogeneic settings, irrespective of graft source. 1 The most common ADs after autologous HSCT are organ-specific ones and in particular haematological diseases like immune thrombocytopenia, autoimmune haemolytic anaemia and Evans syndrome. 2 Otherwise, systemic ADs are less frequent. Imamura et al. ADs can also follow allogeneic HSCT. Clinical case reports suggest that donor autoimmunity can be transferred with the HSCT. Vitiligo, 5 insulin-dependent diabetes mellitus 6 and psoriasis 7 have developed in recipients of HSCT from donors who suffered from these diseases. In favour of the presumption that ADs can be transferred from donor to recipient are findings of clinical disease in the donor and lack of any signs or symptoms in the recipient prior to transplantation. On the other hand, the presence of an AD in the donor does not necessarily result in the transfer to the recipient as suggested by Snowden et al. 8 who described an HSCT from a sibling affected by a severe form of RA where the recipient did not develop the disease after a follow-up period of 4 years. Sturfelt et al. 9 described an analogous case in which the donor suffered from systemic lupus erythematosus.
The transplant recipient can develop a de novo AD triggered by HSCT. Moreover, autoimmunity can occur after transplantation as 'altered immunity' is associated with chronic GVHD (cGVHD). Many of the clinical, histological and serological manifestations of cGVHD are similar to recognised ADs, even if closer examination shows some differences (Table 1) .
However, cGVHD and ADs are not only similar conditions, but can also be associated in the some patient. In fact, it has been shown that GVHD predisposes to the development of ADs after HSCT. 10 Autoimmune clinical manifestations typically occur later during the course of GVHD; what is not known, however, is whether allo-reactive T cells are present early after HSCT or whether these cells emerge later to coincide with these clinical features.
Recently, an important study about the development of new ADs after cord blood transplantation has been published. 11 The study showed that ADs occurred in 6% of patients, the great part of which were organ-specific ones but also one case of RA was described. A multi-centre retrospective study of the European Group for Bone and Marrow Transplantation (EBMT) showed two cases of RA after HSCT was performed for ADs. Can be acknowledged as part of the chronic GVHD symptomatology if the diagnosis is confirmed. 13 
